Insmed Inc Stock Piotroski F Score
| INSM Stock | USD 23.78 0.16 0.67% |
Insmed | Piotroski F Score |
At this time, it appears that Insmed's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
2.0
Piotroski F Score - Frail
1 | Current Return On Assets | Negative | Focus |
2 | Change in Return on Assets | Decreased | Focus |
3 | Cash Flow Return on Assets | Negative | Focus |
4 | Current Quality of Earnings (accrual) | Improving | Focus |
5 | Asset Turnover Growth | Decrease | Focus |
6 | Current Ratio Change | Decrease | Focus |
7 | Long Term Debt Over Assets Change | Higher Leverage | Focus |
8 | Change In Outstending Shares | Decrease | Focus |
9 | Change in Gross Margin | No Change | Focus |
Insmed Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Insmed is to make sure Insmed is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Insmed's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Insmed's financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Shares Diluted | 106.1 M | 123 M |
|
| |||||
| Weighted Average Shares | 106.1 M | 123 M |
|
| |||||
| Current Liabilities | 205.3 M | 190.2 M |
|
| |||||
| Total Liabilities | 1.7 B | 1.6 B |
|
| |||||
| Gross Margin | 0.75 | 0.775 |
|
| |||||
| Total Debt | 1.4 B | 1.3 B |
|
| |||||
| Asset Turnover | 0.19 | 0.202 |
|
| |||||
| Current Assets | 1.4 B | 1.3 B |
|
| |||||
| Total Assets | 1.8 B | 1.7 B |
|
|
Insmed Inc F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Insmed's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Insmed in a much-optimized way.
Click cells to compare fundamentals
About Insmed Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value per Share |
|
Insmed Current Valuation Drivers
We derive many important indicators used in calculating different scores of Insmed from analyzing Insmed's financial statements. These drivers represent accounts that assess Insmed's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Insmed's important valuation drivers and their relationship over time.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 (projected) | ||
| Net Income Per Employee | (869.4K) | (584.7K) | (562.9K) | (709.1K) | (654.3K) | (705.9K) | |
| Average Assets | 690.9M | 726.0M | 799.7M | 1.1B | 1.2B | 1.3B | |
| Earnings Before Interest Taxes and Depreciation Amortization EBITDA | (293.8M) | (205.9M) | (243.0M) | (369.2M) | (431.4M) | (442.8M) | |
| Earnings Before Interest Taxes and Depreciation Amortization USD | (293.8M) | (205.9M) | (243.0M) | (369.2M) | (431.4M) | (442.8M) | |
| Earnings before Tax | (324.1M) | (253.6M) | (292.7M) | (436.4M) | (480.2M) | (492.8M) | |
| Average Equity | 326.3M | 266.6M | 311.2M | 412.0M | 55.5M | 57.0M | |
| Enterprise Value | 755.7M | 2.0B | 3.2B | 3.0B | 3.1B | 2.5B | |
| Free Cash Flow | (271.1M) | (292.9M) | (225.6M) | (370.6M) | (410.3M) | (421.1M) | |
| Invested Capital | 287.6M | 513.0M | 500.2M | 793.9M | 1.5B | 1.6B | |
| Invested Capital Average | 320.5M | 448.3M | 513.2M | 711.5M | 1.2B | 1.3B | |
| Market Capitalization | 1.0B | 2.1B | 3.4B | 3.2B | 2.7B | 2.4B | |
| Tangible Asset Value | 545.9M | 688.6M | 746.9M | 1.0B | 1.5B | 1.6B | |
| Working Capital | 439.2M | 470.0M | 504.1M | 701.9M | 1.1B | 1.2B |
About Insmed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Insmed Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Insmed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Insmed Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey. Insmed operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 613 people.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Insmed without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
| All Next | Launch Module |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Insmed Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Insmed Altman Z Score, Insmed Correlation, Insmed Valuation, as well as analyze Insmed Alpha and Beta and Insmed Hype Analysis. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Insmed Stock analysis
When running Insmed's price analysis, check to measure Insmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insmed is operating at the current time. Most of Insmed's value examination focuses on studying past and present price action to predict the probability of Insmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insmed's price. Additionally, you may evaluate how the addition of Insmed to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Insmed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.29) | Revenue Per Share 2.043 | Quarterly Revenue Growth 0.167 | Return On Assets (0.36) | Return On Equity (14.53) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.